Celularity (CELU) vs NewcelX (NCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NewcelX (NCEL) has outperformed Celularity (CELU) over the past year, losing 22.3% versus a loss of 73.5%. Over five years, CELU leads with a -99.3% price change compared with -99.7% for NCEL. Celularity is the larger company by market cap ($15.0 million vs $14.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELU | NCEL |
|---|---|---|
| Share price | $0.463 | $2.54 |
| Market cap | $15.02M | $14.67M |
| 1-day change | -1.05% | -5.58% |
| YTD return | -58.29% | +33.68% |
| 1-year return | -73.54% | -22.32% |
| 5-year return | -99.31% | -99.65% |
| P/E ratio (TTM) | — | 4.88 |
| EPS (TTM) | $-1.69 | $0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $26.55M | — |
| Revenue growth (YoY) | -51.03% | — |
| Net income (latest FY) | $-91.72M | $-8.30M |
| Gross margin | 24.39% | — |
| Operating margin | -230.92% | — |
| Net margin | -345.45% | — |
| 52-week high | $2.55 | $5.12 |
| 52-week low | $0.42 | $1.83 |
| Distance from 52-week high | -81.84% | -50.39% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +805.51% |
| Average volume | 3.95M | 13.34K |
| Shares outstanding | 32.45M | 5.78M |
| Employees | 115 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NCEL has outperformed CELU by 51.2 percentage points over the past year.
About Celularity
CELU stock →Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
CELU vs NCEL FAQ
Which is bigger, Celularity or NewcelX?
Celularity (CELU) is larger, with a market capitalization of $15.02M compared with $14.67M for NewcelX (NCEL).
Which stock has performed better over the past year, CELU or NCEL?
NCEL returned -22.32% over the past 12 months, compared with -73.54% for CELU (price return, excluding dividends). Past performance does not predict future results.
Are Celularity and NewcelX in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.